The APOBEC3B c.783delG Truncating Mutation Is Not Associated with an Increased Risk of Breast Cancer in the Polish Population
Authors:
- Katarzyna GliniewiczKGKatarzyna Gliniewicz
- Wojciech KluźniakWKWojciech Kluźniak
- Dominika WokołorczykDWDominika Wokołorczyk
- Tomasz HuzarskiTHTomasz Huzarski
- Klaudia StempaKSKlaudia Stempa
- Helena RudnickaHRHelena Rudnicka
- Anna JakubowskaAJAnna Jakubowska
- Marek SzwiecMSMarek Szwiec
- Joanna Jarkiewicz-TretynJJJoanna Jarkiewicz-Tretyn
- Mariusz NaczkMariusz Naczk
- Tomasz KluzTKTomasz Kluz
- Tadeusz DębniakTDTadeusz Dębniak
Open Access
Abstract
The APOBEC3B gene belongs to a cluster of DNA-editing enzymes on chromosome 22 and encodes an activation-induced cytidine deaminase. A large deletion of APOBEC3B was associated with increased breast cancer risk, but the evidence is inconclusive. To investigate whether or not APOBEC3B is a breast cancer susceptibility gene, we sequenced this gene in 617 Polish patients with hereditary breast cancer. We detected a single recurrent truncating mutation (c.783delG, p.Val262Phefs) in four of the 617 (0.65%) hereditary cases by sequencing. We then genotyped an additional 12,484 women with unselected breast cancer and 3740 cancer-free women for the c.783delG mutation. The APOBEC3B c.783delG allele was detected in 60 (0.48%) unselected cases and 19 (0.51%) controls (OR = 0.95, 95% CI 0.56–1.59, p = 0.94). The allele was present in 8 of 1968 (0.41%) familial breast cancer patients from unselected cases (OR = 0.80, 95% CI 0.35–1.83, p = 0.74). Clinical characteristics of breast tumors in carriers of the APOBEC3B mutation and non-carriers were similar. No cancer type was more frequent in the relatives of mutation carriers than in those of non-carriers. We conclude the APOBEC3B deleterious mutation p.Val262Phefs does not confer breast cancer risk. These data do not support the hypothesis that APOBEC3B is a breast cancer susceptibility gene.Keywords
Funding Information
- Narodowe Centrum Nauki (2015/17/B/NZ5/02543)
This publication has 62 references indexed in Scilit:
- Signatures of mutational processes in human cancerNature, 2013
- APOBEC3B can impair genomic stability by inducing base substitutions in genomic DNA in human cellsScientific Reports, 2012
- Rare Mutations in XRCC2 Increase the Risk of Breast CancerThe American Journal of Human Genetics, 2012
- Mutation analysis of RAD51D in non-BRCA1/2 ovarian and breast cancer familiesBritish Journal of Cancer, 2012
- Genetic variants associated with breast-cancer risk: comprehensive research synopsis, meta-analysis, and epidemiological evidenceThe Lancet Oncology, 2011
- Somatic hypermutation of human mitochondrial and nuclear DNA by APOBEC3 cytidine deaminases, a pathway for DNA catabolismProceedings of the National Academy of Sciences, 2011
- Cancer predisposing BARD1 mutations in breast–ovarian cancer familiesBreast Cancer Research and Treatment, 2011
- Estrogen directly activates AID transcription and functionJournal of Experimental Medicine, 2009
- PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility geneNature Genetics, 2006
- Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutationsNature Genetics, 2002